Treatment of patients with Paget's disease of bone.
Paget's disease is a progressive bone disease, monostotic or polyostotic, characterised by hypertrophy of affected bones and accelerated disorganised bone remodelling. It results in bone deformities and pain, with a risk for articular and neurological complications, and fractures. The risk of complications, and thus the therapeutic decision, is a function of the age of the patient, and the severity and the activity of the disease. Bisphosphonates are first-line therapy for Paget's disease, and the advent of the new bisphosphonates permits a dramatic improvement in treatment. The optimal treatment regimen should obtain normalisation or quasi-normalisation of markers of bone remodelling. This result has the potential for a long-term control of the disease.
Roux
C
C
Centre d'Evaluation des Maladies Osseuses, Department of Rheumatologie, Hôpital Cochin, Hopitaux de Paris, Université René Descartes, France.
Dougados
M
M
D015415:Biomarkers; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000473:pathology; D010146:Pain / Q000188:drug therapy; D016896:Treatment Outcome
D015415:Biomarkers; D004164:Diphosphonates